EXOSOMICS SIENA SPA

Their core work

Exosomics Siena is an Italian biotech SME specialized in extracellular vesicles (EVs) and exosome-based diagnostics and therapeutics. They develop technologies for isolating, characterizing, and applying exosomes — particularly for liquid biopsy applications in cancer detection and cell-free therapies. Their core competence lies in membrane sensing peptides for affinity capture of EVs, positioning them as a technology provider in the rapidly growing liquid biopsy market. They contribute primarily as a third-party expert, bringing proprietary EV isolation and analysis capabilities to larger research consortia.

What they specialise in

How they've shifted over time

Early work (2017-2018) centered squarely on cancer liquid biopsies — detecting tumour-derived markers like circulating tumour DNA, tumour-educated platelets, and circulating tumour cells through exosome analysis. By 2020, the focus broadened significantly: while EVs remained central, new directions emerged in therapeutic applications (cardiac repair, cell-free therapy), manufacturing scale-up (affinity capture scaling), and advanced processing tools (microfluidics, magnetic nanoparticles). This shift from purely diagnostic applications toward therapeutics and manufacturing readiness suggests a company maturing from research participation toward commercialization.

Exosomics is moving from diagnostic research toward scalable EV manufacturing and therapeutic applications, suggesting they are preparing their technology platform for commercial-stage partnerships.

How they like to work

Exosomics operates almost exclusively as a specialist contributor rather than a project leader — they have zero coordinator roles and participated mostly as a third party (3 of 4 projects). This is typical of a biotech SME that provides proprietary technology or know-how to larger academic-led consortia. With 47 unique partners across 17 countries from just 4 projects, they embed themselves in large, diverse networks, indicating they are well-connected and trusted as a niche technology provider.

Despite only four projects, Exosomics has built a wide network of 47 partners across 17 countries, reflecting the large consortium sizes typical of MSCA training networks and FET-funded projects. Their reach is genuinely pan-European.

What sets them apart

Exosomics occupies a rare niche as a private company with deep specialization in extracellular vesicle technology — most EV expertise sits in academic labs, not commercial entities. Their combination of proprietary peptide-based capture methods with manufacturing scale-up experience makes them a valuable bridge between academic EV research and industrial application. For consortium builders, they offer something hard to find: an SME that can contribute both scientific depth in EV biology and a pathway toward commercialization.

Highlights from their portfolio

• ELBA
  Their only directly funded project (EUR 258K), a pan-European liquid biopsies training academy covering the full spectrum from tumour DNA to exosome-based diagnostics.
• MARVEL
  Directly tied to their core IP — membrane sensing peptides for scalable EV capture — spanning both diagnostic (bladder cancer) and therapeutic (cardiac repair) applications.
• BOW
  Explores an unusual intersection of organotropicity, magnetic nanoparticles, and microfluidics for EV applications, signaling a push into advanced bioengineering territory.